(Q30984472)

28 June 2017

1 reference

title

Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness (English)

1 reference

28 June 2017

Philip D Harvey

1

1 reference

28 June 2017

Christopher R Bowie

series ordinal

2

1 reference

28 June 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

Expert Opinion on Pharmacotherapy

28 June 2017

published in

1 reference

28 June 2017

volume

6

1 reference

28 June 2017

issue

2

1 reference

28 June 2017

page(s)

337-346

1 reference

Weight gain from novel antipsychotic drugs: need for action

28 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.2.337

A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.2.337

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.2.337

Ziprasidone: a new atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.2.337

Ziprasidone: the fifth atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.2.337

Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.2.337

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.2.337

Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.2.337

5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.2.337

Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.2.337

Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.2.337

Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.2.337

Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.2.337

Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.2.337

21 January 2018

Identifiers

DOI

10.1517/14656566.6.2.337

1 reference

28 June 2017

1 reference